Astellas Pharma Global Development

172 total trials 129 currently recruiting 32 completed

Trial Pipeline

RECRUITING

A Study to Learn How Stargardt-type Eye Conditions Progress in Children and Adults

NCT07425574

RECRUITING Phase 3

A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherapies, in People With Pancreatic Cancer

NCT07409272

RECRUITING Phase 1

A Study of ASP2998 Given by Itself and Given With Standard Therapies in People With Solid Tumors

NCT07287995

RECRUITING Phase 1

A Study to Learn How Fluconazole, Carbamazepine and Itraconazole Affect How the Body Processes ASP3082 in Healthy Adults

NCT07395024

RECRUITING Phase 1

A Study of ASP2138 Given Before Surgery, Then Chemotherapy After Surgery, in People With Pancreatic Ductal Cancer

NCT07024615

RECRUITING Phase 1

A Study of Gilteritinib in Adults With Advanced ALK-positive Non-small Cell Lung Cancer (NSCLC)

NCT07140016

RECRUITING Phase 2

A Phase 2 Study to Evaluate the Effects of ASP5541 in Participants With Prostate Cancer

NCT07005154

RECRUITING Phase 3

A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer

NCT06901531

RECRUITING

A Study to Learn How Avacincaptad Pegol (Izervay™) is Used in Clinical Practice in People Who Have Geographic Atrophy

NCT06779773

RECRUITING Phase 1

A Study to Evaluate the Effects of ASP5502 in Healthy Adults and Adults With Primary Sjögren's Syndrome

NCT06544642

RECRUITING Phase 1

A Study of ASP1002 in Adults for Treatment of Solid Tumors

NCT05719558

RECRUITING Phase 1

A Study of ASP2138 Given by Itself or Given With Other Cancer Treatments in Adults With Stomach Cancer, Gastroesophageal Junction Cancer, or Pancreatic Cancer

NCT05365581

RECRUITING Phase 1

A Study of ASP1570 Taken by Itself, or ASP1570 Taken Together With Either Pembrolizumab, Standard Therapies, or Both, in Adults With Solid Tumors

NCT05083481

RECRUITING Phase 1

A Safety and Dose-finding Study of PRL-02 Depot in Men With Advanced Prostate Cancer

NCT04729114

RECRUITING Phase 2

A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study

NCT02960022

ACTIVE NOT RECRUITING Phase 1

A Study of Zolbetuximab With Chemotherapy in Adults With Pancreatic Cancer

NCT06396091

ACTIVE NOT RECRUITING

A Study Following Women in Menopause Treated With a Non-hormonal Therapy for Hot Flashes and Night Sweats

NCT06049797

ACTIVE NOT RECRUITING Phase 1

A Study of Gilteritinib, Venetoclax and Azacitidine as a Combined Treatment for People Newly Diagnosed With Acute Myeloid Leukemia

NCT05520567

ACTIVE NOT RECRUITING Phase 3

Enfortumab Vedotin and Pembrolizumab vs. Chemotherapy Alone in Untreated Locally Advanced or Metastatic Urothelial Cancer

NCT04223856

ACTIVE NOT RECRUITING Phase 2

A Study to Evaluate Enfortumab Vedotin in Subjects With Locally Advanced or Metastatic Malignant Solid Tumors (EV-202)

NCT04225117

ACTIVE NOT RECRUITING Phase 2

A Study of Zolbetuximab (IMAB362) in Adults With Pancreatic Cancer

NCT03816163

ACTIVE NOT RECRUITING Phase 3

A Study of Zolbetuximab (IMAB362) Plus CAPOX Compared With Placebo Plus CAPOX as First-line Treatment of Subjects With Claudin (CLDN) 18.2-positive, HER2-negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (GLOW).

NCT03653507

ACTIVE NOT RECRUITING Phase 2

A Study of Zolbetuximab (IMAB362) in Adults With Gastric Cancer

NCT03505320

ACTIVE NOT RECRUITING Phase 3

A Study to Compare Zolbetuximab (IMAB362) and Chemotherapy With Placebo and Chemotherapy in Adults With Gastric Cancer.

NCT03504397

ACTIVE NOT RECRUITING Phase 1

A Study of Enfortumab Vedotin Alone or With Other Therapies for Treatment of Urothelial Cancer

NCT03288545

COMPLETED

Experiment to Assess Preferences for Novel Hormonal Therapy and Androgen-deprivation Therapy in Prostate Cancer Patients

NCT06500741

COMPLETED Phase 3

A Study to Find Out if ASP5354 Can Clearly Help Show the Ureter During Surgery in People With or Without Kidney Disease

NCT05999747

COMPLETED Phase 3

A Study to Find Out if ASP5354 Can Clearly Help Show the Ureter During Surgery

NCT05754333

COMPLETED Phase 1

A Study About How ASP5354 Affects the Body in Healthy Adults and in Adults Whose Kidneys do Not Work Well

NCT05495581

COMPLETED Phase 1

A Study to Learn How [14C]ASP0367 is Processed by the Body in Healthy Men

NCT05217901

COMPLETED Phase 1

Study of ASP7517 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors Expressing WT1 Antigen

NCT04837196

COMPLETED Phase 1

A Study to Assess the Safety, Tolerability and Pharmacokinetics of Multiple Doses of ASP8062 With a Single Dose of Morphine in Recreational Opioid Using Participants

NCT04448561

COMPLETED Phase 1

A Study to Assess Bioequivalence of Fezolinetant Formulations in Healthy Female Participants

NCT04277624

COMPLETED Phase 1

Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ASP1617 in Healthy Adult Non-Asian and Japanese Subjects Including Assessment of a Food Effect

NCT04077879

COMPLETED Phase 1

A Study to Assess Potential Interaction Between ASP8062 and Alcohol in Healthy Adult Subjects

NCT04003402

COMPLETED Phase 1

A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MA-0211 in Healthy Adult Subjects Including a Food Effect Cohort

NCT03682484

COMPLETED Phase 2

A Study of ASP2215 (Gilteritinib), Administered as Maintenance Therapy Following Induction/Consolidation Therapy for Subjects With FMS-like Tyrosine Kinase 3 (FLT3/ITD) Acute Myeloid Leukemia (AML) in First Complete Remission

NCT02927262

COMPLETED Phase 1

A Study to Evaluate Safety, Tolerability and Immune Response in Adults Allergic to Peanut After Receiving Intradermal or Intramuscular Administration of ASP0892 (ARA-LAMP-vax), a Single Multivalent Peanut (Ara h1, h2, h3) Lysosomal Associated Membrane Protein DNA Plasmid Vaccine

NCT02851277

COMPLETED Phase 1

Rollover Study for Subjects Who Have Participated in an Astellas Sponsored ASP2215 Trial

NCT02561455

COMPLETED Phase 1

A Study of ASP2215 in Combination With Induction and Consolidation Chemotherapy in Patients With Newly Diagnosed Acute Myeloid Leukemia

NCT02236013

COMPLETED Phase 4

Study to Evaluate the Efficacy, Safety, and Tolerability of Mirabegron in Older Adult Subjects With Overactive Bladder (OAB)

NCT02216214

COMPLETED Phase 2

A Study to Assess the Efficacy and Safety of Enzalutamide With Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2 Positive (HER2+), Androgen Receptor Positive (AR+) Metastatic or Locally Advanced Breast Cancer

NCT02091960

COMPLETED Phase 2

A Rollover Study for Subjects That Have Participated in an Astellas Sponsored Linsitinib Trial

NCT02057380

COMPLETED Phase 1

A Study to Evaluate the Effect of Multiple Doses of Isavuconazole on the Pharmacokinetics of Repaglinide and Caffeine

NCT02128321

COMPLETED Phase 1

A Study to Evaluate the Effect of Multiple Doses of Esomeprazole on the Pharmacokinetics of Isavuconazole

NCT02128893

COMPLETED Phase 1

ASG-15ME is a Study of Escalating Doses of AGS15E Given as Monotherapy in Subjects With Metastatic Urothelial Cancer

NCT01963052

COMPLETED Phase 1

A Study to Evaluate the Effect of Verapamil on the Pharmacokinetics of ASP015K in Healthy Adult Subjects

NCT02111317

COMPLETED Phase 4

A Study to Evaluate the Potential Increased Risk of Seizures Among Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients Treated With Enzalutamide

NCT01977651

COMPLETED Phase 1

Study to Evaluate the Pharmacokinetics of 14C-labeled Isavuconazole Following a Single Oral Dose of 14C-labeled Prodrug Isavuconazonium Sulfate (BAL8557) in Healthy Male Subjects

NCT01813461

COMPLETED Phase 2

A Study to Determine Safety and Tolerability of Enzalutamide (MDV3100) in Combination With Abiraterone Acetate in Bone Metastatic Castration-Resistant Prostate Cancer Patients

NCT01650194

COMPLETED Phase 1

A Phase I Study to Compare 3 Different Strengths of an Extended Release Formulation of ASP015K to an Immediate Release Formulation of ASP015K

NCT01686217

COMPLETED Phase 1

A Study To Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of ASP2408 After Multiple Dose Subcutaneous Injections in Patients With Rheumatoid Arthritis on Methotrexate

NCT02052375

COMPLETED Phase 1

Drug Interaction Study of Multiple Doses of Isavuconazole and a Single Dose of Bupropion

NCT01635972

COMPLETED Phase 1

Drug Interaction Study of Multiple Doses of Isavuconazole and Single Dose of Dextromethorphan in Healthy Adult Subjects

NCT01651325

COMPLETED Phase 1

A Study to Look at How a Single Oral Dose of 14C-OSI-906 is Absorbed, Broken Down and Eliminated in the Body

NCT01529684

COMPLETED Phase 1

Study of the Effect of Repeat Doses of Isavuconazole on Cardiac Repolarization

NCT01565720

COMPLETED Phase 1

A Study to Evaluate a Single Intravenous (IV) Dose Using a New Manufactured Clone and Single Ascending Doses of Subcutaneous (SC) Injections

NCT02150070

What the Pipeline for Astellas Pharma Global Development Shows

According to the ClinicalTrials.gov registry, Astellas Pharma Global Development is linked to 172 US clinical trials across every stage of research activity. Of those, 129 studies are currently recruiting — about 75% of the sponsor's indexed portfolio — and 32 are already marked complete, representing roughly 19% of the total. Recruiting share is one of the more practical signals here: it reflects how much of a sponsor's research is presently open to new participants, while the completed share indicates the depth of finished work that has already contributed registry results. Both counts come directly from the public ClinicalTrials.gov dataset and are refreshed on the registry side; this page mirrors the latest data pull without altering it.

The phase mix for Astellas Pharma Global Development reports 9 late-stage studies (Phase 3 and Phase 4 combined) and 158 earlier-phase studies (Phase 1 and Phase 2). A portfolio weighted toward Phase 3 usually reflects an organization advancing candidates toward regulatory review, where the research centers on comparative efficacy and broader safety across larger populations. A heavier Phase 1 and Phase 2 tilt generally indicates exploratory work — safety, dosing, and early signal detection — and is common among research-forward sponsors that seed many early programs. Phase 4 entries, when present, track interventions already in real-world use and typically focus on long-term safety, effectiveness across subgroups, or formulation comparisons.

The top therapeutic focus area indexed for Astellas Pharma Global Development is Healthy Volunteers with 10 linked trials, and 9 other condition areas appear in the top list above. That distribution is a quick read of where the organization concentrates its research attention; it does not imply product availability, market share, or any clinical endorsement. All numbers on this page come from ClinicalTrials.gov maintained by the National Library of Medicine, and counts can shift as new studies are registered or existing ones update their status. This information is provided for reference and educational purposes only, not as medical, investment, or regulatory advice — verify current details directly with ClinicalTrials.gov before relying on any figure here.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial